AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Ambu

M&A Activity May 31, 2012

Preview not available for this file type.

Download Source File

As of May 31st 2012, Ambu has completed the acquisition of Unomedical's
electrode and diathermy business.

The acquisition is expected to affect all Ambu sales regions. In Europe, Ambu
already has a strong position in the electrode market and, with the
acquisition, will further strengthen its product portfolio. In the USA, there
is a preference for the monitoring electrodes which Unomedical supplies, so
Ambu will now be able to meet, in particular, the demands of the purchasing
organisations for this type of electrode. The acquisition will also strengthen
Ambu’s position in the emerging markets, in which there is a growing demand for
electrodes for monitoring, in particular.

The acquisition comprises two product lines (ECG electrodes and diathermy
plates); equipment and machines at the Unomedical factory in Gloucestershire,
UK; existing inventories; customer relations as well as electrode delivery
contracts. Ambu is not taking over the factory building, but has signed a lease
with the seller. Fifty-seven employees will join Ambu in connection with the
acquisition.

The integration of the factory into Ambu’s business – including supply chain
set-up, HR initiatives and IT integration – will now commence.

Expected effect on revenue

The acquisition is expected to have a positive effect on revenue in FY 2011/12
of approx DKK 15m, while it is not expected to have any appreciable effect on
EBIT after extraordinary expenses in the form of integration and transaction
costs. The EBIT outlook for FY 2011/12 is therefore maintained at the level of
15-15.5%. The integration and transaction costs for Unomedical are expected to
be of approx. DKK 5m in 2011/12.

The outlook for revenue in 2011/12 has been adjusted upwards from DKK
1,025-1,035m to now DKK 1,040-1,050m. For FY 2012/13, the acquisition is
expected to have a positive effect on EBIT and profitability will in H2
subsequently be on a par with Ambu’s existing electrode business.

Contact

Lars Marcher, President & CEO, tel. +45 5136 2490, e-mail: [email protected]

Ambu A/S

Baltorpbakken 13

2750 Ballerup

Tlf. +45 7225 2000

CVR-nr.: 63 64 49 19

www.ambu.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.